Platinum nanoparticles reduce ovariectomy-induced bone loss by decreasing osteoclastogenesis.
- Author:
Woon Ki KIM
1
;
Jin Chun KIM
;
Hyun Jung PARK
;
Ok Joo SUL
;
Mi Hyun LEE
;
Ji Soon KIM
;
Hye Seon CHOI
Author Information
1. Department of Biological Sciences (BK21 Program) and Immunomodulation Research Center, University of Ulsan, Ulsan 680-749, Korea. hschoi@mail.ulsan.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
NFAT2;
osteoclasts;
osteoporosis;
ovariectomy;
platinum nanoparticles;
RANK ligand
- MeSH:
Animals;
Metal Nanoparticles/*administration & dosage;
Mice;
Mice, Inbred C57BL;
NFATC Transcription Factors/metabolism;
*Osteoclasts/drug effects/physiology;
Osteoporosis/drug therapy;
Ovariectomy/adverse effects;
Oxidative Stress/drug effects;
Platinum/*administration & dosage;
*RANK Ligand/genetics/metabolism;
Reactive Oxygen Species/metabolism;
Signal Transduction
- From:Experimental & Molecular Medicine
2012;44(7):432-439
- CountryRepublic of Korea
- Language:English
-
Abstract:
Platinum nanoparticles (PtNP) exhibit remarkable antioxidant activity. There is growing evidence concerning a positive relationship between oxidative stress and bone loss, suggesting that PtNP could protect against bone loss by modulating oxidative stress. Intragastric administration of PtNP reduced ovariectomy (OVX)-induced bone loss with a decreased level of activity and number of osteoclast (OC) in vivo. PtNP inhibited OC formation by impairing the receptor activator of nuclear factor-kappaB ligand (RANKL) signaling. This impairment was due to a decreased activation of nuclear factor-kappaB and a reduced level of nuclear factor in activated T-cells, cytoplasmic 1 (NFAT2). PtNP lowered RANKL-induced long lasting reactive oxygen species as well as intracellular concentrations of Ca2+ oscillation. Our data clearly highlight the potential of PtNP for the amelioration of bone loss after estrogen deficiency by attenuated OC formation.
